Referred to the House Committee on Energy and Commerce.
This bill requires the Secretary of Health and Human Services, through the FDA Commissioner, to create an expedited approval process for supplemental biologics license applications (BLAs) submitted by blood center owners/operators who want to add an apheresis collection device at a location not previously licensed for that device. Under the expedited procedure the FDA must approve such a supplement within 30 days of submission unless there is a specific safety/purity/potency concern at that location or a systemic failure by the owner/operator at other licensed locations.
Speed vs. safety: liberals worry expedited timelines could weaken safety reviews; conservatives emphasize reducing delay while preserving targeted safety authority.
Relative to its intended legislative type, this bill is a narrowly focused administrative directive that clearly mandates an expedited FDA process for specified BLA supplements and sets concrete timelines and basic eligibility criteria.
This bill requires the Secretary of Health and Human Services, through the FDA Commissioner, to create an expedited approval process for supplemental biologics license applications (BLAs) submitted by blood center owners/operators who want to add an apheresis collection device at a location not previously licensed for that device.
Under the expedited procedure the FDA must approve such a supplement within 30 days of submission unless there is a specific safety/purity/potency concern at that location or a systemic failure by the owner/operator at other licensed locations.
The expedited process applies only if the applicant already holds a biologics license for at least one blood center site and either (A) has approvals at three or more FDA-registered locations under that license or (B) is accredited and in good standing by an accreditation organization whose standards the Secretary determines meet or exceed applicable blood collection regulatory requirements.
On content alone, the bill is a modest, technical adjustment to FDA procedure that has plausible bipartisan appeal and limited fiscal impact, increasing its chances. However, the imposition of a short statutory review deadline for biologics-related approvals raises substantive safety and administrative concerns that could slow or block enactment, especially in the Senate or in inter-committee negotiations with FDA oversight interests.
Relative to its intended legislative type, this bill is a narrowly focused administrative directive that clearly mandates an expedited FDA process for specified BLA supplements and sets concrete timelines and basic eligibility criteria. It integrates with existing statutory authority and provides useful high-level structure.
Speed vs. safety: liberals worry expedited timelines could weaken safety reviews; conservatives emphasize reducing delay while preserving targeted safety authority.
These are examples from the analysis, not a ranked list of the most-affected groups.
Speed vs. safety: liberals worry expedited timelines could weaken safety reviews; conservatives emphasize reducing delay while preserving targeted safety authority.
A mainstream liberal would likely welcome the bill's goal of increasing blood collection capacity and reducing delays that can limit lifesaving donations, but would be cautious about speeding approvals without robust safety and equity safeguards.
They would be attentive to whether the policy primarily benefits large national operators versus community or hospital-based blood centers, and would want transparency, strong post-approval monitoring, and protections for donors and recipients.
Concerns would focus on maintaining high standards for safety, avoiding regulatory shortcuts, and ensuring underserved areas benefit.
A centrist/moderate would likely view the bill as a pragmatic, targeted measure to reduce regulatory delays that hinder blood collection capacity, while emphasizing the need to balance speed with safety.
They would support the concept if the FDA retains clear authority to block approvals when safety concerns exist and if implementation includes measurable safeguards and reporting.
Centrists would look for cost-neutral implementation and mechanisms to prevent gaming of eligibility criteria.
A mainstream conservative would generally favor the bill's deregulatory element that shortens approval timelines and reduces bureaucratic delay for life-saving medical infrastructure.
They would emphasize that the measure still preserves FDA authority to block approvals in cases of specific safety issues or systemic failures and that the eligibility tests restrict the expedited pathway to experienced, licensed, or accredited operators.
Their main priorities would be efficiency, reducing unnecessary regulatory friction, and enabling private-sector expansion of donation capacity.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a modest, technical adjustment to FDA procedure that has plausible bipartisan appeal and limited fiscal impact, increasing its chances. However, the imposition of a short statutory review deadline for biologics-related approvals raises substantive safety and administrative concerns that could slow or block enactment, especially in the Senate or in inter-committee negotiations with FDA oversight interests.
The bill has not accumulated any surfaced votes yet.
Speed vs. safety: liberals worry expedited timelines could weaken safety reviews; conservatives emphasize reducing delay while preserving t…
On content alone, the bill is a modest, technical adjustment to FDA procedure that has plausible bipartisan appeal and limited fiscal impac…
Relative to its intended legislative type, this bill is a narrowly focused administrative directive that clearly mandates an expedited FDA process for specified BLA supplements and sets concrete timelines and basic elig…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.